Published in Blood on August 02, 2010
Hepcidin and iron regulation, 10 years later. Blood (2011) 3.80
Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 2.96
Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood (2012) 1.57
Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica (2013) 1.32
Iron homeostasis in host defence and inflammation. Nat Rev Immunol (2015) 1.28
Inhibition of hepcidin transcription by growth factors. Hepatology (2012) 1.17
Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol (2014) 1.04
Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol (2013) 1.03
Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med (2012) 1.01
The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology (2013) 1.00
Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun (2013) 0.99
New insights into iron regulation and erythropoiesis. Curr Opin Hematol (2015) 0.98
High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol (2013) 0.91
Repulsive guidance molecule (RGM) family proteins exhibit differential binding kinetics for bone morphogenetic proteins (BMPs). PLoS One (2012) 0.91
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell (2014) 0.91
Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica (2012) 0.87
Regulation of Iron Metabolism by Hepcidin under Conditions of Inflammation. J Biol Chem (2015) 0.84
Serum-induced up-regulation of hepcidin expression involves the bone morphogenetic protein signaling pathway. Biochem Biophys Res Commun (2013) 0.83
Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact. Lung India (2015) 0.81
Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma. Haematologica (2015) 0.81
Hepcidin in anemia of chronic heart failure. Am J Hematol (2011) 0.80
Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation. Haematologica (2015) 0.79
Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma. Exp Ther Med (2012) 0.79
A multi-scale model of hepcidin promoter regulation reveals factors controlling systemic iron homeostasis. PLoS Comput Biol (2014) 0.79
Hepcidin-minireview. J Clin Diagn Res (2013) 0.78
BMP-2: a culprit for anemia in myeloma. Blood (2010) 0.78
Hepcidin - A novel biomarker with changing trends. Pharmacogn Rev (2015) 0.77
Iron in multiple myeloma. Crit Rev Oncog (2013) 0.77
Regulation of the Iron Homeostatic Hormone Hepcidin. Adv Nutr (2017) 0.75
Myelomagenesis: capturing early microenvironment changes. Semin Hematol (2011) 0.75
Dilemma: Correlation Between Serum Level of Hepcidin and IL-6 in Anemic Myeloma Patients. Med Arch (2016) 0.75
Angiocrine Bmp2 signaling in murine liver controls normal iron homeostasis. Blood (2016) 0.75
Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr (2016) 0.75
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest (2004) 11.05
Multiple myeloma. N Engl J Med (2004) 10.81
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer (1975) 10.04
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Bone morphogenetic proteins. Growth Factors (2004) 8.61
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Multiple myeloma. Blood (2008) 5.88
Immunoassay for human serum hepcidin. Blood (2008) 5.32
Interleukin-6 induces hepcidin expression through STAT3. Blood (2006) 4.24
Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest (2007) 4.09
Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature (2002) 3.67
STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood (2006) 3.38
Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A (2006) 3.13
Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol (2008) 2.29
Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med (Berl) (2009) 2.15
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am (2003) 1.97
A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med (Berl) (2008) 1.71
Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res (2008) 1.57
A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis. Haematologica (2009) 1.35
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
Cytokines and signal transduction. Best Pract Res Clin Haematol (2005) 1.25
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood (2008) 1.09
Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett (2001) 1.02
Signaling crosstalk underlying synergistic induction of astrocyte differentiation by BMPs and IL-6 family of cytokines. FEBS Lett (2001) 1.00
The role of STAT, AP-1, E-box and TIEG motifs in the regulation of hepcidin by IL-6 and BMP-9: lessons from human HAMP and murine Hamp1 and Hamp2 gene promoters. Blood Cells Mol Dis (2007) 0.93
Altered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta type I receptor mutant. Digestion (2005) 0.89
The biology of multiple myeloma. J Cancer Res Clin Oncol (2000) 0.87
Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res (2009) 0.85
Hepcidin and multiple myeloma related anemia. Med Hypotheses (2005) 0.81
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest (2004) 11.05
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood (2002) 7.58
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet (2003) 5.82
Immunoassay for human serum hepcidin. Blood (2008) 5.32
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med (2007) 5.18
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Regulation of iron metabolism by hepcidin. Annu Rev Nutr (2006) 3.96
Hepcidin is decreased in TFR2 hemochromatosis. Blood (2004) 3.46
Defensins of vertebrate animals. Curr Opin Immunol (2002) 3.41
Suppression of hepcidin during anemia requires erythropoietic activity. Blood (2006) 3.32
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther (2005) 3.27
Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol (2002) 3.13
Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood (2005) 3.10
The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell (2007) 2.99
Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 2.96
Hepcidin in iron overload disorders. Blood (2005) 2.88
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Systemic iron homeostasis. Physiol Rev (2013) 2.69
Hepcidin and disorders of iron metabolism. Annu Rev Med (2011) 2.67
Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood (2005) 2.66
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood (2009) 2.65
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.61
Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A (2005) 2.60
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood (2007) 2.51
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol (2009) 2.45
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Retracted The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab (2008) 2.25
Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol (2008) 2.25
Proinflammatory state, hepcidin, and anemia in older persons. Blood (2010) 2.19
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest (2010) 2.18
Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol (2002) 2.17
The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A (2005) 2.10
Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood (2005) 2.08
Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol (2007) 2.02
Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics (2005) 1.97
Detection, evaluation, and management of iron-restricted erythropoiesis. Blood (2010) 1.93
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res (2002) 1.93
A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood (2010) 1.89
Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem (2005) 1.89
The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem (2002) 1.89
The role of hepcidin in iron metabolism. Acta Haematol (2009) 1.88
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol (2003) 1.88
Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol (2002) 1.86
Iron sequestration and anemia of inflammation. Semin Hematol (2009) 1.85
Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology (2011) 1.82
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol (2003) 1.82
Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology (2010) 1.82
Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol (2006) 1.81
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res (2007) 1.79
Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood (2007) 1.78
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood (2006) 1.77
Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis (2007) 1.76
Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem (2008) 1.74
Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest (2007) 1.72
Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta (2006) 1.72
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res (2009) 1.72
Antimicrobial components of vaginal fluid. Am J Obstet Gynecol (2002) 1.67
Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res (2002) 1.66
Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood (2004) 1.64
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect Dis (2004) 1.63
Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica (2006) 1.62
The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood (2005) 1.60
Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer (2007) 1.58
Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol (2002) 1.58
Increased genomic copy number of DEFA1/DEFA3 is associated with susceptibility to severe sepsis in Chinese Han population. Anesthesiology (2010) 1.58
Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res (2008) 1.57
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol (2006) 1.56
Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol (2006) 1.55
By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol (2003) 1.54
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma (2009) 1.54